Top

Journal of Thrombosis and Thrombolysis

Published in:

Open Access 01-01-2018 | Letter to the Editor

Dabigatran level monitoring prior to idarucizumab administration in patients requiring emergent cardiac surgery

Authors: Radoslaw Litwinowicz, Janusz Konstanty-Kalandyk, Tadeusz Goralczyk, Krzysztof Bartus, Piotr Mazur

Published in: Journal of Thrombosis and Thrombolysis | Issue 1/2018

Excerpt

To the Editor, …

Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383(9921):955–962. https://doi.org/10.1016/s0140-6736(13)62343-0 CrossRefPubMed

Caldeira D, Rodrigues FB, Barra M, Santos AT, de Abreu D, Goncalves N, Pinto FJ, Ferreira JJ, Costa J (2015) Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis. Heart 101(15):1204–1211. https://doi.org/10.1136/heartjnl-2015-307489 CrossRefPubMed

Di Nisio M, van Es N, Buller HR (2016) Deep vein thrombosis and pulmonary embolism. Lancet 388(10063):3060–3073. https://doi.org/10.1016/s0140-6736(16)30514-1 CrossRefPubMed

Douketis JD, Healey JS, Brueckmann M, Fraessdorf M, Spyropoulos AC, Wallentin L, Oldgren J, Reilly P, Ezekowitz MD, Connolly SJ, Yusuf S, Eikelboom JW (2016) Urgent surgery or procedures in patients taking dabigatran or warfarin: analysis of perioperative outcomes from the RE-LY trial. Thromb Res 139:77–81. https://doi.org/10.1016/j.thromres.2016.01.004 CrossRefPubMed

Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI (2015) Idarucizumab for dabigatran reversal. N Engl J Med 373(6):511–520. https://doi.org/10.1056/NEJMoa1502000 CrossRefPubMed

Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI (2017) Idarucizumab for dabigatran reversal—full cohort analysis. N Engl J Med 377(5):431–441. https://doi.org/10.1056/NEJMoa1707278 CrossRefPubMed

Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P (2016) Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. https://doi.org/10.1093/eurheartj/ehw058 PubMed

Mazur P, Darocha T, Filip G, Grudzien G, Drwila R, Kapelak B (2016) Idarucizumab for dabigatran reversal in patients with atrial fibrillation undergoing emergency surgery for acute aortic syndrome. Pol Arch Med Wewn 126(7–8):579–581. https://doi.org/10.20452/pamw.3470 PubMed

Dyke C, Aronson S, Dietrich W, Hofmann A, Karkouti K, Levi M, Murphy GJ, Sellke FW, Shore-Lesserson L, von Heymann C, Ranucci M (2014) Universal definition of perioperative bleeding in adult cardiac surgery. J Thorac Cardiovasc Surg 147(5):1458–1463. https://doi.org/10.1016/j.jtcvs.2013.10.070 CrossRefPubMed

10.

Heidbuchel H, Verhamme P, Alings M, Antz M, Diener H-C, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P (2015) Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 17(10):1467–1507CrossRefPubMed

11.

Raval AN, Cigarroa JE, Chung MK, Diaz-Sandoval LJ, Diercks D, Piccini JP, Jung HS, Washam JB, Welch BG, Zazulia AR, Collins SP (2017) Management of patients on non-vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting: a scientific statement from the American Heart Association. Circulation 135(10):e604–e633. https://doi.org/10.1161/cir.0000000000000477 CrossRefPubMed

12.

Simon A, Domanovits H, Ay C, Sengolge G, Lewy JH, Spiel AO (2017) Recommended dose of Idarucizumab may not always be sufficient for sustained reversal of dabigatran. J Thromb Haemost. https://doi.org/10.1111/jth.13706 PubMed

13.

Vosko MR, Bocksrucker C, Drwila R, Dulicek P, Hauer T, Mutzenbach J, Schlimp CJ, Spinler D, Wolf T, Zugwitz D (2017) Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases. J Thromb Thrombolysis 43(3):306–317. https://doi.org/10.1007/s11239-017-1476-2 CrossRefPubMedPubMedCentral

14.

Vanassche T, Greinacher A, Verhamme P (2016) Reversal of dabigatran by idarucizumab: when and how? Expert Rev Hematol 9(6):519–528. https://doi.org/10.1080/17474086.2016.1184569 CrossRefPubMed

15.

Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ (2014) 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 130(25):2354–2394. https://doi.org/10.1161/cir.0000000000000133 CrossRefPubMed

16.

Bijak M, Bobrowski M (2010) The importance of thrombin inhibitors in the antithrombotic pharmacotherapy. Postępy Nauk Medycznych 10:819–825

17.

Samuelson BT, Cuker A (2017) Measurement and reversal of the direct oral anticoagulants. Blood Rev 31(1):77–84. https://doi.org/10.1016/j.blre.2016.08.006 CrossRefPubMed

18.

Cuker A (2016) Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication. J Thromb Thrombolysis 41(2):241–247. https://doi.org/10.1007/s11239-015-1282-7 CrossRefPubMed

Title: Dabigatran level monitoring prior to idarucizumab administration in patients requiring emergent cardiac surgery
Authors: Radoslaw Litwinowicz
Janusz Konstanty-Kalandyk
Tadeusz Goralczyk
Krzysztof Bartus
Piotr Mazur
Publication date: 01-01-2018
Publisher: Springer US
Published in: Journal of Thrombosis and Thrombolysis / Issue 1/2018
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-017-1587-9

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Dabigatran level monitoring prior to idarucizumab administration in patients requiring emergent cardiac surgery

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2018

Correction to: Generation and characterization of tissue-type plasminogen activator transgenic rats

O blood type is a risk factor for upper gastrointestinal bleeding

A sticky situation: myocardial infarction in a young woman with immune thrombocytopenia on eltrombopag and a history of mediastinal radiation

Initial and long term impact of a multi-disciplinary task force in the diagnosis and management of heparin-induced thrombocytopenia

Heparin, coumarin, protein C, antithrombin, fibrinolysis and other clotting related resistances: old and new concepts in blood coagulation

Contemporary use of P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction referred to primary percutaneous coronary interventions in Poland: Data from ORPKI national registry

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page